GlassScriptPhysician profile
Michael William Vavra
NPI 1114182359
$6,892.82
in general payments reported to CMS, 2019-2025
58 companies · $1,766 in 2025
The $1,766 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $719 · 2020: $333 · 2021: $367 · 2022: $955 · 2023: $1,047 · 2024: $1,706 · 2025: $1,766.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,502 · Education: $16.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,501.66 |
| Education | $16.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $863.79 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Mdd US Operations, LLC | $519.60 | 2019-2024 | Gocovri, Gocovri |
| Lundbeck LLC | $418.93 | 2022-2025 | Vyepti |
| Biogen, INC. | $359.07 | 2019-2025 | Vumerity, Tysabri |
| Ucb, INC. | $341.06 | 2019-2025 | Fintepla, Rystiggo, Briviact |
| Novartis Pharmaceuticals Corporation | $247.17 | 2019-2025 | |
| Eisai INC. | $246.80 | 2019-2025 | |
| Supernus Pharmaceuticals, INC. | $221.28 | 2019-2022 | |
| Emd Serono, INC. | $215.25 | 2023-2025 | Mavenclad, Mavenclad |
| Acadia Pharmaceuticals INC | $203.14 | 2022-2025 | Nuplazid |
| Argenx US, INC. | $165.73 | 2023-2025 | |
| Celgene Corporation | $155.82 | 2022-2025 | Zeposia |
| Sunovion Pharmaceuticals INC. | $152.45 | 2019-2021 | |
| Sk Life Science, INC. | $144.54 | 2021-2025 | Xcopri |
| Pfizer INC. | $141.67 | 2023-2025 |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Vavra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.